- About Us
- Services & Solutions
- WuXi XDC – Bioconjugation
- News & Media
Offering End-to-End Solutions
SHANGHAI, Mar. 30, 2017 — WuXi Biologics (“WuXi Bio”) (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, today announced that it had received the 2017 Asia-Pacific Best Bioprocessing Excellence Award from IMAPAC, a leading consulting firm.
Asia-Pacific Bioprocessing Excellence Awards aims to recognize outstanding leaders and trend-setters of today, and inspire innovators of tomorrow. Featuring top bioprocessing and biomanufacturing experts in the industry, along with the latest advances in technologies and best practices in manufacturing, WuXi Biologics has been recognized for its outstanding performance that facilitating biomanufacturing excellence at enhanced speed, reduced cost and superior quality.
As an open-access biologics technology platform, WuXi Biologics opened its state-of-the-art biologics manufacturing facilities at Wuxi city in 2012, which is the first in China that met cGMP standards of the United States, the European Union, and China. In 2015, WuXi began construction of world’s largest mammalian cell culture manufacturing facility using disposable bioreactors with a planned manufacturing capacity of 30000L, and completed construction of Asia’s largest perfusion biologics manufacturing facility using disposable bioreactors in 2016, offering end-to-end solution to our worldwide customers and partners.
“WuXi Biologics is honored to be recognized by IMAPAC,” said Dr. Chris Chen, CEO of WuXi Biologics, “The award truly reflects all of the efforts we have put forth to provide our customers with high-quality and best-in-class service to help accelerate biologics development from concept to commercialization.”
About WuXi Biologics
WuXi Biologics (stock code: 2269.HK), a Hong Kong-listed company, is a leading global open-access biologics technology platform offering end-to-end solutions to empower organizations to discover, develop and manufacture biologics from concept to commercial manufacturing. Our company history and achievements demonstrate our commitment to providing a truly ONE-stop service offering and strong value proposition to our global clients. As of June 30, 2019, there were a total of 224 integrated projects, including 106 projects in pre-clinical development stage, 102 projects in early-phase (phase I and II) clinical development, 15 projects in late-phase (phase III) development and 1 project in commercial manufacturing. With total estimated capacity for biopharmaceutical production planned in China, Ireland, Singapore and US exceeding 280,000 liters by 2022, we will provide our biomanufacturing partners with a robust and premier-quality global supply chain network. For more information on WuXi Biologics, please visit www.wuxibiologics.com.